治疗诱导的快速耐药性是由基因组混乱和多倍体巨型癌细胞驱动的
Steven D Horne1, Jing Christine Ye2, Guo Liu1
1Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48201, USA.
矛盾的是,癌症治疗可以通过快速基因组重组诱导耐药性,从而挑战传统观点. 这一发现需要重新考虑癌症治疗策略,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 进化生物学 进化生物学
背景情况:
- 癌症药物治疗往往面临抗药性,传统上归因于先前存在的细胞变异.
- 最近的发现表明基因组混乱中介的宏观进化是快速耐药性的新机制.
研究的目的:
- 通过基因组重组,调查有效的癌症治疗可以矛盾地诱导快速耐药性的假设.
- 在癌症模型中检查治疗诱导的耐药性的实时动态.
主要方法:
- 采用快速耐药模型,在不同剂量的药物下跟踪癌细胞的表型和基因型变化.
- 观察到的变化包括生长-死亡动态和多倍体巨型癌细胞 (PGCC) 的出现.
主要成果:
- 尽管频率低,但观察到从有效杀死转变为治疗诱导的耐药性.
- 驱动抗性的机制包括增加杀戮强度,放大异质性,大量的初始种群规模和细胞不稳定性.
- 一个双相癌症进化模型解释了这些治疗诱导的耐药性结果.
结论:
- 癌症药物耐药性可能由治疗诱导的基因组重组引起,与先前存在的变异不同.
- 这一发现挑战了当前的癌症治疗策略,并表明癌症耐药性可能与细菌耐药性有根本差异.
- 重新考虑治疗策略对于解决这种现象至关重要.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
08:32Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
相关概念视频
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancers Originate from Somatic Mutations in a Single Cell
DNA Damage can Stall the Cell Cycle
